25.10.2022 BRAIN Biotech AG  DE0005203947

EQS-News: BRAIN Biotech and Bonumose collaborate on enzymes for the production of rare monosaccharides


EQS-News: BRAIN Biotech AG / Key word(s): Alliance
BRAIN Biotech and Bonumose collaborate on enzymes for the production of rare monosaccharides

25.10.2022 / 09:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

BRAIN Biotech and Bonumose collaborate on enzymes for the production of rare monosaccharides

Zwingenberg, Germany and Charlottesville, VA, USA, 25 October 2022 – BRAIN Biotech AG, a leading European industrial biotechnology specialist, and rare sugars expert Bonumose, announced today that they have reached initial project milestones as part of their strategic collaboration. The companies aim to improve the performance of several enzymes that catalyze cascade reactions in the continuous production of low-calorie, ultra low-glycemic, naturally occurring sweeteners.

Bonumose has developed a patented process for producing tagatose and allulose which eliminates several processing steps and significantly increases yields during the production process. The company uses multiple enzymes within the synthesis cascades and BRAIN Biotech is optimizing several of these enzymes using enzyme engineering.

Patrick Lorenz, Vice President, Strategic Initiatives BioScience at BRAIN Biotech says: “BRAIN Biotech´s enzyme technology suite has proven once again to deliver on a customer´s challenging protein engineering targets. Based on rational structure- and sequence-guided design we improved individual enzymes and their cumulative performance in cascades to better match production process requirements. The ultimate aim is making production of Bonumose´s beneficial rare sugars even more cost efficient.”

Ed Rogers, Co-founder and CEO at Bonumose, states: “Tagatose and allulose have 92 % and 70 % the sweetness of sucrose but only 38 % and 10 % of the calories. Our mission is to produce them in a low cost production process from commodity carbohydrates. Our development collaborator BRAIN Biotech has passed the third milestone in the collaboration and thanks to their enzyme engineering, analytics and enzyme assay expertise we are on track and confident to meet our developmental objectives“.



BRAIN Biotech AG (“BRAIN”) is a leading European industrial biotechnology specialist with a focus on nutrition, health and the environment. As a technology and solutions provider the company supports the biologization of industries with bio-based products and processes. From contract R&D with industrial partners to advancing own disruptive incubator projects and customized enzyme products, BRAIN’s broad cutting-edge biotech expertise and its agile teams are key to success.

BRAIN Biotech AG, Germany, is the parent company of the international BRAIN Group, distributing specialty B2B products like enzymes or bioactive natural products. The BRAIN Group has its own fermentation or production facilities in Continental Europe, UK and the US, which together with the associated biotechnological solution competency complete the value chain within the group.

As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption and to actively advance common societal goals. Our products and services target at least five of the UN SDGs directly.

Since its IPO in 2016, BRAIN Biotech AG is listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).


About Bonumose

Bonumose is a growth-stage startup food ingredient and enzyme innovation company based near Charlottesville, Virginia. Bonumose is supported by global strategic investors and “food for health”-focused institutional investors, and an expanding network of global collaboration partners across the value chain. Bonumose developed and patented the methods for continuous production of high-purity tagatose from low-cost, plant-based starch. Bonumose’s process includes upcycling by-product/sidestream starch left over from its supply chain partners’ food production. Beyond food ingredients, Bonumose also is developing enzyme solutions for dietary supplements, crop protection, animal nutrition, and other globally-significant industries. Due to the global public health significance of Bonumose’s innovations, the World Economic Forum recently designated Bonumose as a “Technology Pioneer” for 2022. Bonumose operates with a philosophy of Business as a Moral Imperative.


Media Contact

Dr. Stephanie Konle

Public Relations & Corporate Communications

Phone: +49 6251 9331-70

Email: [email protected]


Contact Investor Relations

Martina Schuster

Investor Relations

Phone: +49 6251 9331-69

Email: [email protected]


Follow @BRAINbiotech on Twitter (https://twitter.com/BRAINbiotech) and @BRAIN Biotech AG on LinkedIn (https://www.linkedin.com/company/brainbiotech)



This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management.

Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance by, and future developments at, BRAIN Biotech AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors.

BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.


25.10.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language: English
Company: BRAIN Biotech AG
Darmstädter Straße 34-36
64673 Zwingenberg
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: [email protected]
Internet: www.brain-biotech.com
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1470901

End of News EQS News Service

1470901  25.10.2022 CET/CEST


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022
Umsatzerlöse1 22,79 24,11 27,05 38,56 38,23 38,39 45,51
EBITDA1,2 -12,36 -7,70 -6,55 -2,50 -3,88 -2,53 -1,31
EBITDA-Marge3 -54,23 -31,94 -24,21 -6,48 -10,15 -6,59 -2,88
EBIT1,4 -13,81 -9,37 -9,57 -7,20 -8,23 -6,55 -5,65
EBIT-Marge5 -60,60 -38,86 -35,38 -18,67 -21,53 -17,06 -12,42
Jahresüberschuss1 -14,43 -9,40 -8,37 -11,12 -9,02 -4,68 -6,34
Netto-Marge6 -63,32 -38,99 -30,94 -28,84 -23,59 -12,19 -13,93
Cashflow1,7 -8,68 -5,80 -5,42 -3,38 -4,77 -3,10 -1,49
Ergebnis je Aktie8 -0,97 -0,58 -0,45 -0,61 -0,52 -0,25 -0,30
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Baker Tilly

BRAIN Biotech
WKN Kurs in € Einschätzung Börsenwert in Mio. €
520394 6,300 Halten 137,64
KGV 2024e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 -13,97
4,98 - 2,78 -117,82
Dividende '22 in € Dividende '23e in € Div.-Rendite '22e
in %
0,00 0,00 0,00 08.03.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
27.02.2023 25.05.2023 30.08.2023 16.01.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-2,94% -2,31% 7,88% -29,69%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu BRAIN Biotech AG  ISIN: DE0005203947 können Sie bei EQS abrufen

Biotechnologie , 520394 , BNN , XETR:BNN